Citigroup Raises TMO Price Target to $800
Key Points
- Citigroup maintained a Buy rating on Thermo Fisher Scientific Inc. on October 23, 2026, while lifting its price target to $800.00 from $685.00.
- Citigroup's $800 price target implies 18.25% upside from Thermo Fisher Scientific Inc.'s ($TMO) current $676.54 share price.
- Thermo Fisher Scientific Inc. recently traded around $676.54, sitting 0.4% above its event-day close of $673.82 on October 23, 2026.
- Wall Street maintains a strong buy consensus across 25 analyst opinions, with a mean price target of $750.92 ahead of earnings on January 28, 2027.
Get Thermo Fisher Scientific text alerts
We text you when insiders, Congress, analysts or big funds move on $TMO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Thermo Fisher Scientific Inc. alert may contain errors. Disclosures
Citigroup maintained its Buy rating on Thermo Fisher Scientific Inc. (NYSE: TMO) on October 23, 2026, while raising its price target from $685.00 to $800.00. According to the firm's research note, the updated target points to added room for growth as the healthcare giant continues its work in life sciences solutions.
TMO
Thermo Fisher Scientific Inc.
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Citigroup's Call on Thermo Fisher Scientific
Citigroup kept its positive stance on the company with a Buy rating on October 23, 2026, bumping up its target price by $115.00 to $800.00. This update adds to a series of target adjustments from major Wall Street institutions following recent business developments in the diagnostics and research sector.
Other Institutional Activity in Thermo Fisher Scientific
Large funds continue to adjust their holdings in the healthcare provider. Campbell Newman Asset Management grew its holdings by 30,933 shares, ending with 32,744 shares worth about $22,103,837. Franklin Resources, Inc. held 7,271,514 shares valued at roughly $4,919,469,921 after adding 458,515 shares to its position.
Thermo Fisher Scientific Inc. Stock Down 2.5%
The stock recently traded around $676.54 as of October 23, 2026, sitting up about 0.4% from an event close of $673.82. Shares sit well above both their 50-day and 200-day moving averages.
$TMO price target
Thermo Fisher Scientific Inc. daily closes and this analyst's $800 target. Not advice.
Recent Earnings
The company generated $47,351,001,088 in trailing revenue with earnings of $18.96 per share. The firm reported a net margin of 14.9% and a return on equity of 13.4%. Its next earnings report is scheduled for January 28, 2027.
Dividend
The company pays an annual dividend rate of $1.88 per share, translating to a dividend yield of 0.28%.
Insider Buying and Selling at Thermo Fisher Scientific Inc.
Company insiders executed several stock sales prior to the analyst update. Officer Lisa P Britt sold 11,440 shares on August 19, 2026. Chief Executive Officer Marc N Casper sold 20,000 shares on August 21, 2026, and another 275 shares on August 24, 2026. President Gianluca Pettiti sold 4,133 shares on August 31, 2026.
Analysts Set New Price Targets
Wall Street firms have actively updated their views on the stock. On October 22, 2026, Barclays maintained its overweight rating and lifted its target from $750.00 to $775.00. RBC Capital kept its sector perform rating and raised its target from $580.00 to $730.00. TD Cowen maintained a buy rating and increased its target to $810.00 from $760.00. Stifel kept a buy rating and raised its target from $650.00 to $775.00. Overall, the stock carries a strong buy recommendation across 25 analyst opinions.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. Headquartered in Waltham, Massachusetts, the firm operates through four main segments to support research, clinical trials, and diagnostic testing across the global healthcare landscape.
Bottom Line
Citigroup's updated target highlights continued confidence in the healthcare provider's trajectory. Investors will look toward the upcoming earnings release on January 28, 2027, for further updates on financial performance.
Related Filing Alerts
Source: Citigroup's rating change on $TMO (Oct 23, 2026). Written by software, not financial advice. How we make alerts